TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abbisko Cayman Limited ( (HK:2256) ) just unveiled an announcement.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the China National Medical Products Administration for its investigational oral PD-L1 inhibitor, ABSK043, in combination with Allist’s KRAS G12C inhibitor, glecirasib, for treating NSCLC patients with KRAS G12C mutation. This development marks a significant step in Abbisko’s strategic collaboration with Allist, aiming to enhance treatment options for NSCLC. The clearance allows for a Phase 2 clinical study to evaluate the safety and efficacy of the drug combination, potentially positioning Abbisko as a key player in the NSCLC treatment landscape.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company, through its subsidiary Abbisko Therapeutics, specializes in creating small molecule inhibitors targeting immune checkpoints and mutations in cancer cells, with a market focus on non-small cell lung cancer (NSCLC) and other advanced solid tumors.
Average Trading Volume: 5,310,737
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.89B
Find detailed analytics on 2256 stock on TipRanks’ Stock Analysis page.